Company Analysis
Sign in

Novartis AG (NVS)

NYSE: NVS · Pharmaceutical Preparations · Basel, CH · filing with the SEC since 2001
Full chart Alerts Compare
Grade5.5
◀ Past 6.9● Present 6.1▶ Future 3.2
6 est.
OverviewBusinessFinancialsGradeForecastSentimentOwnershipPeopleFilingsPatents Chart

Patents

US patents through Dec 31, 2025 · PatentsView, from the USPTO’s Open Data Portal · read Oct 27, 2026

3,941 patents granted to the 3 names below, as the owner printed on each patent when it was granted. A later sale, a lapse or an expiry is not read, so this is what was granted to Novartis AG’s names, not what it holds today.

Patents granted
3,941
3,843 utility, 77 design, 15 reissue, 3 statutory invention registration, 3 plant, 1976 to Dec 31, 2025
Granted in 2025
74
Against 93 in 2024 and 72 in 2023
Applications published
4,226
167 of them in 2025
Names they are printed under
3
its own name
By yearGrantedApplications published
'11'12'13'14'15'16'17'18'19'20'21'22'23'24'25
Each pair is one calendar year. Applications are published about eighteen months after filing, so the newest years read low.
What they are aboutgrants since 2021
Pharmaceuticals252
Organic fine chemistry80
Biotechnology61
Medical technology31
Chemical engineering6
Analysis of biological materials4
Computer technology2
Measurement2
Handling1
The main technology area of each patent, in the World Intellectual Property Organization’s 35 fields.
Under which name3 counted
NOVARTIS AG its own name
CH, as the owner printed on each patent. 192 more under the same name are not counted (printed in US, printed in SE, printed in CN)
3,940 granted
1,912 published
Novartis AG its own name
named as the applicant on its applications, in CH. 12 more under the same name are not counted (printed in US, printed in DE, printed in SE)
0 granted
2,314 published
Novartis AB its own name
CH, as the owner printed on each patent
1 granted
0 published
Newest grantseach row opens the USPTO’s own copy
GrantedPatentTitleFieldOwner as printed
Dec 16, 202512,497,616Compounds targeting PMP22 for the treatment of Charcot-Marie-Tooth diseaseOrganic fine chemistryNOVARTIS AG
Dec 16, 202512,497,449Methods of treating autoimmune diseases using interleukin-17 (IL-17) antagonistsPharmaceuticalsNOVARTIS AG
Dec 9, 202512,492,265Anti-IgE antibody therapy for multiple food allergiesPharmaceuticalsNOVARTIS AG
Dec 9, 202512,491,231Methods of treating metabolic disorders with FGF21 variantsPharmaceuticalsNOVARTIS AG
Dec 2, 202512,485,173Pharmaceutical products and stable liquid compositions of IL-17 antibodiesPharmaceuticalsNOVARTIS AG
Dec 2, 202512,485,172Pharmaceutical products and stable liquid compositions of IL-17 antibodiesPharmaceuticalsNOVARTIS AG
Nov 25, 202512,479,817Substituted 3-(1-oxoisoindolin-2-yl)piperidine-2,6-dione derivatives and uses thereofOrganic fine chemistryNOVARTIS AG
Nov 18, 202512,473,273Quinoline compounds and compositions for inhibiting EZH2Organic fine chemistryNOVARTIS AG
Nov 11, 202512,466,821Antiviral pyridopyrazinedione compoundsPharmaceuticalsNOVARTIS AG
Nov 11, 202512,466,808Aminopyridine derivatives and their use as selective ALK-2 inhibitorsOrganic fine chemistryNOVARTIS AG
Newest applications publishedan application is a clue, never a plan
PublishedApplicationTitleFieldOwner as printed
Dec 25, 20252025/0388698FGF21 MIMETIC ANTIBODIES AND USES THEREOFPharmaceuticalsNovartis AG
Dec 25, 20252025/0387523COMBINATION THERAPY OF RADIONUCLIDE COMPLEXPharmaceuticalsNovartis AG
Dec 25, 20252025/0387504ANTIBODY-DRUG CONJUGATES OF ANTINEOPLASTIC COMPOUNDS AND METHODS OF USE THEREOFPharmaceuticalsNovartis AG
Dec 18, 20252025/0382650NUCLEIC ACID LIGATION METHODBiotechnologyNovartis AG
Dec 18, 20252025/0382621IMMUNE EFFECTOR CELL THERAPIES WITH ENHANCED EFFICACYBiotechnologyNovartis AG
Dec 18, 20252025/0382365ANTIBODY MOLECULES TO LAG-3 AND USES THEREOFPharmaceuticalsNovartis AG
Dec 11, 20252025/0376487LIPID-MODIFIED NUCLEIC ACID COMPOUNDS AND METHODSPharmaceuticalsNovartis AG
Dec 11, 20252025/0375446METHODS OF TREATING CHRONIC SPONTANEOUS URTICARIA USING A BRUTON'S TYROSINE KINASE INHIBITORPharmaceuticalsNovartis AG
Dec 4, 20252025/0369967CELL-BASED ASSAY FOR MEASURING DRUG PRODUCT POTENCYBiotechnologyNovartis AG
Dec 4, 20252025/0368750SHP INHIBITOR COMPOSITIONS AND USES FOR CHIMERIC ANTIGEN RECEPTOR THERAPYBiotechnologyNovartis AG
What it applied for, 2024 to 2025: Pharmaceuticals 215 · Organic fine chemistry 51 · Biotechnology 49 · Medical technology 11 · Analysis of biological materials 4 · Macromolecular chemistry, polymers 1.

A patent is counted where the owner printed on it when it was granted carries the company’s own name, a former name, the name of a subsidiary its annual report lists, or its own name with a patent-holding phrase (Technology Licensing, Intellectual Property and the like), once the legal form, case and punctuation are set aside, and prints a country that name counts in. PatentsView’s data are published under the Creative Commons Attribution 4.0 licence. Source: PatentsView's granted patents and pre-grant publications, disambiguated, from the USPTO's Open Data Portal, through Dec 31, 2025, read Oct 27, 2026.

SI Assistanton NVS · research, not advice